Z53 Therapeutics, LLC is designing first-in-class novel therapeutics to target tumors with mutations in the tumor suppressor gene, p53.

Industry Categories

Industry Biomedical
Sub-industry Drug-Discovery
Focus Areas
Focus Areas - detailed

University

University Rutgers
Principal Investigator Darren Carpizo, M.D. - Cancer Institute of New Jersey, Rutgers Biomedical and Health Sciences

Company

Web http://z53therapeutics.com
Incubator / Accelerator / Lab Facility
Address Cleveland, OH
Phone
Email

Timeline

  • 2015 – Founded

No files attached to this page.

Add a New Comment